Company
Headquarters: Hulin, China
Employees: 3,321
CN¥10.27 Billion
CNY as of Jan. 1, 2025
US$1.41 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥3.12 B |
| EBITDA | CN¥914.1 M |
| Gross Profit TTM | CN¥1.45 B |
| Profit Margin | 20.96% |
| Operating Margin | 10.07% |
| Quarterly Revenue Growth | -26.30% |
Heilongjiang ZBD Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SSE: 603567 wb_incandescent